Study to Evaluate the Effects of NMRA-323511 Among Healthy Elderly and Adults With Agitation Associated With Dementia Due to Alzheimer's Disease
Public ClinicalTrials.gov record NCT06546995. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b, Randomized, Double-blind, Placebo-controlled Pilot Study to Evaluate the Effects of NMRA-323511 Among Healthy Elderly and Adults With Agitation Associated With Dementia Due to Alzheimer's Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study consists of 2 parts, Part A and Part B. Part A is a single center, randomized, double-blind, placebo-controlled cohort designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of NMRA-323511 among healthy elderly. Part B is a multicenter, randomized, double-blinded, placebo-controlled, parallel-group cohort to evaluate the safety, tolerability, and efficacy of NMRA-323511 among adults with Agitation Associated with Dementia due to Alzheimer's Disease. Part A consists of a Screening Period (up to 28 days), a 10-day Treatment Period, and a 10- day Follow-up clinic visit after last dose of study treatment. Part B consists of a Screening Period (up to 28 days), an 8-week Treatment Period, and a 10-day Follow-up clinic visit after last dose of study treatment.
Study identification
- NCT ID
- NCT06546995
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 87 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 55 Years to 90 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 9, 2024 (Actual)
- Primary completion
- Nov 19, 2025 (Actual)
- Completion
- Nov 19, 2025 (Actual)
- Last update posted
- May 22, 2026
2024 – 2025
United States locations
- U.S. sites
- 26
- U.S. states
- 12
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Neumora Investigator Site | Chandler | Arizona | 85286 | — |
| Neumora Investigator Site | Tempe | Arizona | 85283 | — |
| Neumora Investigator Site | Costa Mesa | California | 92626 | — |
| Neumora Investigator Site | Lomita | California | 90717 | — |
| Neumora Investigator Site | Walnut Creek | California | 94596 | — |
| Neumora Investigator Site | Bradenton | Florida | 34205 | — |
| Neumora Investigator Site | Greenacres City | Florida | 33467 | — |
| Neumora Investigator Site | Hallandale | Florida | 33009 | — |
| Neumora Investigator Site | Hialeah | Florida | 33016 | — |
| Neumora Investigator Site | Miami | Florida | 33126 | — |
| Neumora Investigator Site | Miami | Florida | 33137 | — |
| Neumora Investigator Site | Miami | Florida | 33155 | — |
| Neumora Investigator Site | Miami Springs | Florida | 33166 | — |
| Neumora Investigator Site | Orlando | Florida | 32807 | — |
| Neumora Investigator Site | Pembroke Pines | Florida | 33024 | — |
| Neumora Investigator Site | Port Orange | Florida | 32127 | — |
| Neumora Investigator Site | Atlanta | Georgia | 30318 | — |
| Neumora Investigator Site | Honolulu | Hawaii | 96817 | — |
| Neumora Investigator Site | Boise | Idaho | 83704 | — |
| Neumora Investigator Site | Belmont | Massachusetts | 02478 | — |
| Neumora Investigator Site | Troy | Michigan | 48085 | — |
| Neumora Investigator Site | Toms River | New Jersey | 08755 | — |
| Neumora Investigator Site | Brooklyn | New York | 11229 | — |
| Neumora Investigator Site | East Syracuse | New York | 13057 | — |
| Neumora Investigator Site | Charlotte | North Carolina | 28204 | — |
| Neumora Investigator Site | Mesquite | Texas | 75149 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06546995, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 22, 2026 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06546995 live on ClinicalTrials.gov.